GSE118816 Myo1c knockdown podocyte 2 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE118816_Myo1c knockdown_podocyte_2_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE118816_Myo1c knockdown_podocyte_2_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE118816_Myo1c knockdown_podocyte_2_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE118816_Myo1c knockdown_podocyte_2_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

ral guanine nucleotide dissociation stimulator like 2

Gene

HLA complex P5

Gene

BAIAP2 divergent transcript

Gene

long intergenic non-protein coding RNA 2593

Gene

long intergenic non-protein coding RNA 973

Gene

clustered mitochondria homolog pseudogene 3

Gene

PAXIP1 divergent transcript

Gene

uncharacterized LOC389602

Gene

SMG1 pseudogene 1

Gene

SYT9 antisense RNA 1

  • Gene

    ral guanine nucleotide dissociation stimulator like 2



  • Gene

    BAIAP2 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 2593


  • Gene

    long intergenic non-protein coding RNA 973


  • Gene

    clustered mitochondria homolog pseudogene 3


  • Gene

    PAXIP1 divergent transcript


  • Gene

    uncharacterized LOC389602


  • Gene

    SMG1 pseudogene 1


  • Gene

    SYT9 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.